

Schrödinger to Participate in BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery

4/9/2021

NEW YORK--(BUSINESS WIRE)--Apr. 9, 2021-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrödinger, will participate in a panel during the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery. The panel will take place virtually on Friday, April 16, at 10:00 a.m. ET.

The “on demand” webcast can be accessed under "News & Events" in the investors section of Schrödinger’s **website**, <https://ir.schrodinger.com/news-and-events/event-calendar> and will be archived for approximately 7 days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on **LinkedIn** and **Twitter**.

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20210409005031/en/>

Jaren Irene Madden

Schrödinger, Inc.

jaren.madden@schrodinger.com

617-286-6264

Stephanie Simon (media)

Ten Bridge Communications

617-581-9333

Source: Schrödinger